



## Clinical trial results:

**A prospective, open-label, multicentre phase-II-trial to evaluate the efficacy and safety of a sequential regimen of Bendamustine followed by GA101 (Obinutuzumab) and ABT-199 (Venetoclax) followed by ABT-199 and GA101 maintenance in CLL patients.**

### Summary

EudraCT number	2014-000580-40
Trial protocol	DE
Global end of trial date	17 December 2024

### Results information

Result version number	v1 (current)
This version publication date	27 January 2026
First version publication date	27 January 2026
Summary attachment (see zip file)	CLL2-BAG_primary endpoint analysis (CLL2-BAG_primary endpoint analysis_Lancet Oncol_20180817PC.pdf)

### Trial information

#### Trial identification

Sponsor protocol code	CLL2-BAG
-----------------------	----------

#### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02401503
WHO universal trial number (UTN)	-
Other trial identifiers	Sponsor-Number: uni-koeln-1750

Notes:

### Sponsors

Sponsor organisation name	UNIVERSITY OF COLOGNE
Sponsor organisation address	ALBERTUS-MAGNUS-PLATZ, COLOGNE, Germany, 50923
Public contact	Julia Blau, Study Office of the GCLLSG, Department I of Internal Medicine, University Hospital, 50937 Cologne, +49 022147888220, julia.blau@uk-koeln.de
Scientific contact	DR. MED. PAULA CRAMER, Study Office of the GCLLSG, Department I of Internal Medicine, University Hospital, 50937 Cologne, +49 022147888220, paula.cramer@uk-koeln.de

Notes:

### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

---

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	09 May 2025
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	17 December 2024
Was the trial ended prematurely?	No

Notes:

---

## General information about the trial

Main objective of the trial:

The primary objective of the study was to evaluate the efficacy of a sequential regimen of two optional debulking cycles of bendamustine, followed by a combination therapy of obinutuzumab (GA101) and venetoclax (ABT-199) for induction treatment and a MRD-tailored combination therapy of these two drugs for maintenance treatment. Primary endpoint was the overall response rate 12 weeks after start of the last induction cycle.

After an amendment, patients with progression and treatment indication according to iwCLL criteria could receive a retreatment with venetoclax and obinutuzumab.

---

Protection of trial subjects:

Safety measures to prevent or to manage known risks associated with CLL, such as infections or cytopenia or known adverse reactions related to any of the IMPs have been included in the protocol, including sections how to prevent and manage known side effect and detailed instruction about modifications and treatment discontinuation. The protocol includes sections with prohibited, permitted and medication used with caution for each study medication, especially for known interactions with CYP3A4 inhibitors or inducers.

---

Background therapy:

Chemoimmunotherapy is the standard of care in first-line treatment of CLL. In patients  $\leq 65$  years, the combination of fludarabine, cyclophosphamid and rituximab was considered standard treatment, while patients  $>65$  years usually received bendamustine plus rituximab. With the introduction of the glycoengineered, humanized type II anti-CD20 antibody GA101 (obinutuzumab), the combination of GA101 and chlorambucil has become the new standard for patients with CLL and relevant comorbidities and/or an impaired renal function.

Since several targeted agents such as the Btk-inhibitor ibrutinib (formerly PCI-32765), the PI3K-inhibitor CAL-101 (idelalisib) and the Bcl-2-antagonist venetoclax (ABT-199, GDC-0199) have become available, the treatment landscape for CLL as faced profound changes.

The GCLLSG proposed the concept of a tailored and targeted treatment aiming for a total eradication of MRD (so called "sequential triple-T" concept) with a debulking treatment followed by induction treatment with an antibody and a kinase inhibitor or Bcl-2-antagonist, followed by a MRD-tailored maintenance.

The CLL2-BAG trial followed the sequential triple-T concept and investigated a sequential regimen of the Bcl-2-antagonist ABT-199 (GDC-0199) and the anti-CD20-antibody GA101 (obinutuzumab) in an induction and a maintenance phase, in patients with previously untreated and relapsed/refractory CLL. After an amendment, a retreatment with the same agents was allowed for patients with progression. Primary endpoint of the study is the evaluation of the overall response rate at final restaging at the end of induction treatment (12 weeks after the start of the last induction cycle).

Secondary endpoints of the study include further efficacy parameters and safety assessments for initial venetoclax plus obinutuzumab therapy and retreatment.

---

Evidence for comparator:

Not applicable

Actual start date of recruitment	06 May 2015
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Germany: 66
Worldwide total number of subjects	66
EEA total number of subjects	66

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	42
From 65 to 84 years	24
85 years and over	0

## Subject disposition

### Recruitment

#### Recruitment details:

Between 6th May 2015 and 4th January 2016, 66 patients were enrolled. All received at least one dose of study medication. Three patients were later excluded from the full analysis set.

### Pre-assignment

#### Screening details:

A total of 71 patients were screened for eligibility; 5 patients were excluded: 3 didn't require treatment, 1 died during screening, and 1 had impaired renal function.

66 patients initiated study treatment. Of these, 63 patients received at least two complete cycles of induction treatment and were included in the full analysis set.

### Period 1

Period 1 title	Overall trial (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

### Arms

Arm title	Bendamustine debulking (optional), venetoclax, obinutuzumab
-----------	---

#### Arm description:

Two cycles of optional debulking with bendamustine were administered before induction in patients with high tumor load (ALC < 25 x10<sup>9</sup>/l or lymph nodes < 5cm). Obinutuzumab was started in the first induction cycle (days 1, 8, and 15) and repeated on day 1 of cycles 2-6.

Venetoclax ramp up (over 5 weeks up to 400 mg) was initiated on day 1 of cycle 2. Induction treatment was administered for a total of 6 cycles, each with a duration of 28 days. Before start of maintenance, two staging assessments were performed (4 weeks and 12 weeks after start of the last induction cycle). Venetoclax intake was continued during this phase of staging. During maintenance, venetoclax dosage was the same, the interval of obinutuzumab infusions was extended to 12 weeks, each maintenance cycle had a duration of 84 days. Maintenance was continued until progression, unacceptable toxicity, maintenance cycle 8 or 3 months after confirmation of achievement of undetectable MRD in patients with (clinical) CR/CRi.

Arm type	Experimental
Investigational medicinal product name	Bendamustine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder for concentrate and solution for solution for infusion
Routes of administration	Intravenous use

#### Dosage and administration details:

Patients should receive both cycles of debulking treatment even if the patient's tumor burden is reduced to the above-defined threshold.

Debulking treatment should be stopped after the 1st cycle only if severe adverse events occur. In each of the 2 cycles bendamustine is administered intravenously on two consecutive days, the cycle is repeated after 28 days.

#### Bendamustine i.v. infusion:

##### Cycles 1-2:

Day 1: bendamustine 70mg/m<sup>2</sup> i.v.

Day 2: bendamustine 70mg/m<sup>2</sup> i.v.

Investigational medicinal product name	Venetoclax
Investigational medicinal product code	ABT 199
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

---

**Dosage and administration details:**

The daily intake of venetoclax starts with a weekly dose ramp-up to final dose on day 1 of induction cycle 2.

**Induction cycle 2:**

Days 1-7 venetoclax 20mg (2 tabl. at 10mg),  
days 8-14 venetoclax 50mg (1 tabl. at 50mg),  
days 15-21 venetoclax 100mg (1 tabl. at 100mg),  
days: 22-28 venetoclax 200mg (2 tabl. at 100mg).

**Induction cycles 3-6:**

Days 1-28 venetoclax 400mg (4 tabl. at 100mg).

Before the start of the maintenance treatment, two staging assessments will be performed. During this phase of staging, the intake of venetoclax is continued at the same dosage. There is no interruption between induction and maintenance treatment.

**Maintenance cycle 1-8:**

Days 1-28 venetoclax 400mg (4 tabl. at 100mg).

Investigational medicinal product name	Obinutuzumab
Investigational medicinal product code	GA 101
Other name	
Pharmaceutical forms	Concentrate and solvent for solution for injection/infusion
Routes of administration	Intravenous use

**Dosage and administration details:**

Obinutuzumab (GA101) i.v. infusion:

**Induction**

Cycles 1: Day 1: GA101 100mg i.v.

Day 1 (or 2): GA101 900mg i.v.

Day 8: GA101 1000mg i.v.

Day 15: GA101 1000mg i.v.

Cycles 2-6: Day 1: GA101 1000mg i.v.

**Maintenance:**

Cycles 1-8: Day 1: GA101 1000mg i.v.

<b>Number of subjects in period 1</b>	Bendamustine debulking (optional), venetoclax, obinutuzumab
Started	66
Completed	50
Not completed	16
Adverse event, serious fatal	2
New CLL treatment	1
Adverse event, non-fatal	8
Progression of disease	4
Patient refused treatment/did not cooperate	1

## Baseline characteristics

### Reporting groups

Reporting group title	Overall trial (overall period)
-----------------------	--------------------------------

Reporting group description:

Full analysis set [FAS]

Reporting group values	Overall trial (overall period)	Total	
Number of subjects	66	66	
Age categorical			
Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	0	0	
Adolescents (12-17 years)	0	0	
Adults (18-64 years)	42	42	
From 65-84 years	24	24	
85 years and over	0	0	
Age continuous			
Units: years			
median	59		
inter-quartile range (Q1-Q3)	54 to 67	-	
Gender categorical			
Units: Subjects			
Female	16	16	
Male	50	50	
Binet stage			
Units: Subjects			
Binet A	17	17	
Binet B	18	18	
Binet C	31	31	
IGHV mutational status			
Units: Subjects			
unmutated	49	49	
mutated	16	16	
missing information	1	1	
CLL-IPI risk group			
Units: Subjects			
low	3	3	
intermediate	19	19	
high	28	28	
very high	13	13	
missing information	3	3	
TP 53 mutational status			
Units: Subjects			

unmutated	47	47	
mutated	18	18	
missing information	1	1	
del 17p			
Units: Subjects			
no	52	52	
yes	11	11	
missing information	3	3	
complex karyotype			
Units: Subjects			
Non-complex (< 3 aberrations)	43	43	
complex (≥ 3 aberrations)	22	22	
missing information	1	1	

## Subject analysis sets

Subject analysis set title	Full analysis set
Subject analysis set type	Full analysis

Subject analysis set description:

This dataset includes all patients enrolled to the trial who received at least two complete cycles of induction therapy. All primary and secondary efficacy endpoints refer to the full analysis set.

Reporting group values	Full analysis set		
Number of subjects	63		
Age categorical			
Units: Subjects			
In utero	0		
Preterm newborn infants (gestational age < 37 wks)	0		
Newborns (0-27 days)	0		
Infants and toddlers (28 days-23 months)	0		
Children (2-11 years)	0		
Adolescents (12-17 years)	0		
Adults (18-64 years)	40		
From 65-84 years	23		
85 years and over	0		
Age continuous			
Units: years			
median	59		
inter-quartile range (Q1-Q3)	53 to 67		
Gender categorical			
Units: Subjects			
Female	16		
Male	47		
Binet stage			
Units: Subjects			
Binet A	17		
Binet B	17		
Binet C	29		
IGHV mutational status			
Units: Subjects			

unmutated	46		
mutated	16		
missing information	1		
CLL-IPI risk group			
Units: Subjects			
low	3		
intermediate	19		
high	26		
very high	12		
missing information	3		
TP 53 mutational status			
Units: Subjects			
unmutated	45		
mutated	17		
missing information	1		
del 17p			
Units: Subjects			
no	49		
yes	11		
missing information	3		
complex karyotype			
Units: Subjects			
Non-complex (< 3 aberrations)	41		
complex (≥ 3 aberrations)	21		
missing information	1		



## End points

### End points reporting groups

Reporting group title	Bendamustine debulking (optional), venetoclax, obinutuzumab
Reporting group description:	
Two cycles of optional debulking with bendamustine were administered before induction in patients with high tumor load (ALC < 25 x10 <sup>9</sup> /l or lymph nodes < 5cm). Obinutuzumab was started in the first induction cycle (days 1, 8, and 15) and repeated on day 1 of cycles 2-6. Venetoclax ramp up (over 5 weeks up to 400 mg) was initiated on day 1 of cycle 2. Induction treatment was administered for a total of 6 cycles, each with a duration of 28 days. Before start of maintenance, two staging assessments were performed (4 weeks and 12 weeks after start of the last induction cycle). Venetoclax intake was continued during this phase of staging. During maintenance, venetoclax dosage was the same, the interval of obinutuzumab infusions was extended to 12 weeks, each maintenance cycle had a duration of 84 days. Maintenance was continued until progression, unacceptable toxicity, maintenance cycle 8 or 3 months after confirmation of achievement of undetectable MRD in patients with (clinical) CR/CRi.	
Subject analysis set title	Full analysis set
Subject analysis set type	Full analysis
Subject analysis set description:	
This dataset includes all patients enrolled to the trial who received at least two complete cycles of induction therapy. All primary and secondary efficacy endpoints refer to the full analysis set.	

### Primary: Overall response rate (ORR) at end of induction treatment

End point title	Overall response rate (ORR) at end of induction treatment <sup>[1]</sup>
End point description:	
The ORR is defined as the proportion of patients having achieved a CR/CRi, clinical CR/CRi, or PR at the final restaging at end of induction treatment. If the response assessment was missing at the final restaging, the initial response assessment (or interim staging) was counted instead if available. Patients without any documented response assessment were kept and labeled as 'non-responder' in the analysis.	
End point type	Primary
End point timeframe:	
At final restaging, which was 12 weeks after the start of the last cycle of induction treatment	

#### Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The ORR of the BAG regimen was compared with the benchmark of P0=75%, using a two-sided one-sample binomial test. With an overall response rate of 95.2%, the efficacy of the BAG-regimen can be concluded (Exact 95% Clopper-Pearson confidence-interval: 86.7%-99.0%; p-value < 0.001)

<b>End point values</b>	Full analysis set			
Subject group type	Subject analysis set			
Number of subjects analysed	63			
Units: Percentage				
arithmetic mean (confidence interval 95%)	95.2 (86.7 to 99.0)			

### Statistical analyses

No statistical analyses for this end point

### Secondary: Progression-free survival (PFS)

End point title	Progression-free survival (PFS)
-----------------	---------------------------------

End point description:

PFS was calculated from the date of registration to the date of first disease progression (per IWCLL response criteria, unless documented before start of the induction treatment) or death by any cause, whichever occurred first. These were counted as events for the PFS analysis. Start of a subsequent CLL treatment after the study treatment was neither considered an event nor a reason for censoring. Patients without a documented PFS event at data cut-off were censored at the date of the last assessment at which they were event-free.

End point type	Secondary
----------------	-----------

End point timeframe:

Data for this endpoint were collected from the first study visit until the last visit of each study subject.

End point values	Full analysis set			
Subject group type	Subject analysis set			
Number of subjects analysed	63			
Units: Percentage				
number (not applicable)				
5-year survival	47.9			
6-year survival	41.0			
7-year survival	34.2			
Median PFS (months)	57.3			

Attachments (see zip file)	PFS from registration for FAS/CLL2-BAG_PFS from
----------------------------	---

### Statistical analyses

No statistical analyses for this end point

### Secondary: Measureable residual disease (MRD) in peripheral blood (PB) at end of induction treatment

End point title	Measureable residual disease (MRD) in peripheral blood (PB) at end of induction treatment
-----------------	---

End point description:

Undetectable measurable residual disease (uMRD) is defined as less than 1 CLL cell among 10.000 leukocytes, i.e.  $<10^{-4}$ . MRD values are categorized into three different MRD levels: negative ( $<10^{-4}$ ), intermediate ( $\geq 10^{-4}$  and  $<10^{-2}$ ) and high ( $\geq 10^{-2}$ ).

End point type	Secondary
----------------	-----------

End point timeframe:

At final restaging, which is 12 weeks after the start of the last cycle of induction treatment.

End point values	Full analysis set			
Subject group type	Subject analysis set			
Number of subjects analysed	63			
Units: Patients				
< 10-4	57			
≥ 10-4 & < 10-2	3			
≥ 10-2	1			
Missing information	2			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Overall survival (OS)

End point title	Overall survival (OS)
-----------------	-----------------------

End point description:

Overall survival (OS) was calculated from the date of registration to the date of death by any cause. Patients, who were alive at the time of data cut-off, were censored at the timepoint of last visit they were assessed to be alive after registration.

End point type	Secondary
----------------	-----------

End point timeframe:

Data for this endpoint were collected from the date of registration until last visit of each study subject.

End point values	Full analysis set			
Subject group type	Subject analysis set			
Number of subjects analysed	63 <sup>[2]</sup>			
Units: Percent				
number (not applicable)				
5-year survival	87.7			
6-year survival	87.7			
7-year survival	85.1			
Median OS (months)	0			

Notes:

[2] - The median overall survival was not reached.

<b>Attachments (see zip file)</b>	OS from registration for FAS/CLL2-BAG_OS from
-----------------------------------	---

## Statistical analyses

No statistical analyses for this end point

## Secondary: Time to next treatment (TTNT)

End point title	Time to next treatment (TTNT)
-----------------	-------------------------------

End point description:

Time to next treatment (TTNT) was calculated from the date of registration to the date of first

documented initiation of a subsequent CLL treatment (including retreatment in case of a disease progression). These were counted as events for TTNT. Subjects, who have not experienced initiation of subsequent CLL treatment at the time of data cut-off, were censored at the date of last information the patient was assessed as being event-free.

End point type	Secondary
End point timeframe:	
Data for this endpoint were collected from the date of registration until last visit of each study subject.	

<b>End point values</b>	Full analysis set			
Subject group type	Subject analysis set			
Number of subjects analysed	63			
Units: percent				
number (not applicable)				
5-year survival	60.3			
6-year survival	50.8			
7-year survival	38.7			
Median TTNT (months)	74.8			

<b>Attachments (see zip file)</b>	TTNT from registration for FAS/CLL2-BAG_TTNT from
-----------------------------------	---

### Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Timeframe for AE

Adverse event reporting additional description:

AE additional description

Assessment type	Non-systematic
-----------------	----------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	19.0
--------------------	------

### Reporting groups

Reporting group title	RR patient
-----------------------	------------

Reporting group description: -

Reporting group title	FL patient
-----------------------	------------

Reporting group description: -

Serious adverse events	RR patient	FL patient	
Total subjects affected by serious adverse events			
subjects affected / exposed	26 / 31 (83.87%)	26 / 35 (74.29%)	
number of deaths (all causes)	11	2	
number of deaths resulting from adverse events	5	2	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Basal cell carcinoma	Additional description: Basal cell carcinoma		
subjects affected / exposed	1 / 31 (3.23%)	1 / 35 (2.86%)	
occurrences causally related to treatment / all	0 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder cancer	Additional description: Bladder cancer		
subjects affected / exposed	0 / 31 (0.00%)	1 / 35 (2.86%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bowen's disease	Additional description: Bowen's disease		
subjects affected / exposed	1 / 31 (3.23%)	0 / 35 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Breast cancer	Additional description: Breast cancer		

subjects affected / exposed	0 / 31 (0.00%)	1 / 35 (2.86%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malignant melanoma	Additional description: Malignant melanoma		
subjects affected / exposed	1 / 31 (3.23%)	0 / 35 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malignant pleural effusion	Additional description: Malignant pleural effusion		
subjects affected / exposed	0 / 31 (0.00%)	1 / 35 (2.86%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastatic bronchial carcinoma	Additional description: Metastatic bronchial carcinoma		
subjects affected / exposed	0 / 31 (0.00%)	1 / 35 (2.86%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neuroendocrine carcinoma of the skin	Additional description: Neuroendocrine carcinoma of the skin		
subjects affected / exposed	1 / 31 (3.23%)	0 / 35 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostatic adenoma	Additional description: Prostatic adenoma		
subjects affected / exposed	1 / 31 (3.23%)	0 / 35 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Prostate cancer	Additional description: Prostate cancer		
subjects affected / exposed	1 / 31 (3.23%)	3 / 35 (8.57%)	
occurrences causally related to treatment / all	0 / 1	1 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Squamous cell carcinoma	Additional description: Squamous cell carcinoma		
subjects affected / exposed	2 / 31 (6.45%)	0 / 35 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Richter's syndrome	Additional description: Richter's syndrome		

subjects affected / exposed	0 / 31 (0.00%)	1 / 35 (2.86%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Renal cell carcinoma	Additional description: Renal cell carcinoma		
subjects affected / exposed	1 / 31 (3.23%)	0 / 35 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Squamous cell carcinoma of skin	Additional description: Squamous cell carcinoma of skin		
subjects affected / exposed	2 / 31 (6.45%)	0 / 35 (0.00%)	
occurrences causally related to treatment / all	2 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
Hypertensive crisis	Additional description: Hypertensive crisis		
subjects affected / exposed	1 / 31 (3.23%)	0 / 35 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral arterial occlusive disease	Additional description: Peripheral arterial occlusive disease		
subjects affected / exposed	1 / 31 (3.23%)	0 / 35 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Surgical and medical procedures			
Lesion excision	Additional description: Lesion excision		
subjects affected / exposed	0 / 31 (0.00%)	1 / 35 (2.86%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lipoma excision	Additional description: Lipoma excision		
subjects affected / exposed	0 / 31 (0.00%)	1 / 35 (2.86%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tooth extraction	Additional description: Tooth extraction		
subjects affected / exposed	0 / 31 (0.00%)	1 / 35 (2.86%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration			

site conditions			
Pyrexia	Additional description: Pyrexia		
subjects affected / exposed	2 / 31 (6.45%)	2 / 35 (5.71%)	
occurrences causally related to treatment / all	2 / 2	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Immune system disorders			
Cytokine release syndrome	Additional description: Cytokine release syndrome		
subjects affected / exposed	0 / 31 (0.00%)	1 / 35 (2.86%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Reproductive system and breast disorders			
Benign prostatic hyperplasia	Additional description: Benign prostatic hyperplasia		
subjects affected / exposed	1 / 31 (3.23%)	0 / 35 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Nasal obstruction	Additional description: Nasal obstruction		
subjects affected / exposed	0 / 31 (0.00%)	1 / 35 (2.86%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pleural effusion	Additional description: Pleural effusion		
subjects affected / exposed	1 / 31 (3.23%)	0 / 35 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary hypertension	Additional description: Pulmonary hypertension		
subjects affected / exposed	1 / 31 (3.23%)	0 / 35 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychiatric disorders			
Panic attack	Additional description: Panic attack		
subjects affected / exposed	1 / 31 (3.23%)	0 / 35 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Investigations			



Blood creatinine increased subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Blood creatinine increased		
	0 / 31 (0.00%)	2 / 35 (5.71%)	
	0 / 0	2 / 2	
	0 / 0	0 / 0	
Injury, poisoning and procedural complications Infusion related reaction subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Infusion related reaction		
	4 / 31 (12.90%)	2 / 35 (5.71%)	
	4 / 4	2 / 2	
	0 / 0	0 / 0	
Cardiac disorders Acute myocardial infarction subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Acute myocardial infarction		
	1 / 31 (3.23%)	1 / 35 (2.86%)	
	0 / 1	1 / 1	
	0 / 0	0 / 0	
Acute coronary syndrome subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Acute coronary syndrome		
	1 / 31 (3.23%)	0 / 35 (0.00%)	
	1 / 1	0 / 0	
	0 / 0	0 / 0	
Cardiac failure subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Cardiac failure		
	0 / 31 (0.00%)	1 / 35 (2.86%)	
	0 / 0	0 / 1	
	0 / 0	0 / 1	
Atrial flutter subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Atrial flutter		
	1 / 31 (3.23%)	0 / 35 (0.00%)	
	0 / 2	0 / 0	
	0 / 0	0 / 0	
Atrial fibrillation subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Atrial fibrillation		
	0 / 31 (0.00%)	1 / 35 (2.86%)	
	0 / 0	0 / 1	
	0 / 0	0 / 0	
Coronary artery disease subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Coronary artery disease		
	1 / 31 (3.23%)	2 / 35 (5.71%)	
	0 / 1	0 / 2	
	0 / 0	0 / 0	

Coronary artery stenosis subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Coronary artery stenosis		
	0 / 31 (0.00%)	1 / 35 (2.86%)	
	0 / 0	0 / 1	
	0 / 0	0 / 0	
Myocardial infarction subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Myocardial infarction		
	1 / 31 (3.23%)	1 / 35 (2.86%)	
	1 / 1	1 / 1	
	0 / 0	0 / 0	
Nervous system disorders Carotid arteriosclerosis subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Carotid arteriosclerosis		
	1 / 31 (3.23%)	0 / 35 (0.00%)	
	0 / 1	0 / 0	
	0 / 0	0 / 0	
Carotid artery stenosis subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Carotid artery stenosis		
	1 / 31 (3.23%)	0 / 35 (0.00%)	
	0 / 1	0 / 0	
	0 / 0	0 / 0	
Dizziness subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Dizziness		
	1 / 31 (3.23%)	0 / 35 (0.00%)	
	0 / 1	0 / 0	
	0 / 0	0 / 0	
Facial paresis subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Facial paresis		
	1 / 31 (3.23%)	0 / 35 (0.00%)	
	0 / 1	0 / 0	
	0 / 0	0 / 0	
Ischaemic stroke subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Ischaemic stroke		
	1 / 31 (3.23%)	0 / 35 (0.00%)	
	0 / 1	0 / 0	
	0 / 0	0 / 0	
Multiple sclerosis subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	Additional description: Multiple sclerosis		
	1 / 31 (3.23%)	0 / 35 (0.00%)	
	0 / 1	0 / 0	
	0 / 0	0 / 0	
Progressive multiple sclerosis	Additional description: Progressive multiple sclerosis		

subjects affected / exposed	1 / 31 (3.23%)	0 / 35 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Syncope	Additional description: Syncope		
subjects affected / exposed	0 / 31 (0.00%)	1 / 35 (2.86%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
Anaemia	Additional description: Anaemia		
subjects affected / exposed	1 / 31 (3.23%)	0 / 35 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Febrile neutropenia	Additional description: Febrile neutropenia		
subjects affected / exposed	2 / 31 (6.45%)	1 / 35 (2.86%)	
occurrences causally related to treatment / all	2 / 3	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemolysis	Additional description: Haemolysis		
subjects affected / exposed	1 / 31 (3.23%)	0 / 35 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neutropenia	Additional description: Neutropenia		
subjects affected / exposed	3 / 31 (9.68%)	1 / 35 (2.86%)	
occurrences causally related to treatment / all	3 / 3	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombocytopenia	Additional description: Thrombocytopenia		
subjects affected / exposed	3 / 31 (9.68%)	1 / 35 (2.86%)	
occurrences causally related to treatment / all	4 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eye disorders			
Ectropion	Additional description: Ectropion		
subjects affected / exposed	1 / 31 (3.23%)	0 / 35 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rhegmatogenous retinal detachment	Additional description: Rhegmatogenous retinal detachment		

subjects affected / exposed	1 / 31 (3.23%)	0 / 35 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Dysphagia	Additional description: Dysphagia		
subjects affected / exposed	0 / 31 (0.00%)	1 / 35 (2.86%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal haemorrhage	Additional description: Gastrointestinal haemorrhage		
subjects affected / exposed	1 / 31 (3.23%)	0 / 35 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Inguinal hernia	Additional description: Inguinal hernia		
subjects affected / exposed	2 / 31 (6.45%)	0 / 35 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
Cholelithiasis	Additional description: Cholelithiasis		
subjects affected / exposed	1 / 31 (3.23%)	0 / 35 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic cirrhosis	Additional description: Hepatic cirrhosis		
subjects affected / exposed	0 / 31 (0.00%)	1 / 35 (2.86%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
Acute kidney injury	Additional description: Acute kidney injury		
subjects affected / exposed	1 / 31 (3.23%)	1 / 35 (2.86%)	
occurrences causally related to treatment / all	0 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
Facet joint syndrome	Additional description: Facet joint syndrome		

subjects affected / exposed	1 / 31 (3.23%)	0 / 35 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteoporosis	Additional description: Osteoporosis		
subjects affected / exposed	1 / 31 (3.23%)	0 / 35 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Bacterial infection	Additional description: Bacterial infection		
subjects affected / exposed	2 / 31 (6.45%)	0 / 35 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Bronchitis	Additional description: Bronchitis		
subjects affected / exposed	2 / 31 (6.45%)	1 / 35 (2.86%)	
occurrences causally related to treatment / all	0 / 2	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Covid-19 pneumonia	Additional description: Covid-19 pneumonia		
subjects affected / exposed	1 / 31 (3.23%)	1 / 35 (2.86%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Covid-19	Additional description: Covid-19		
subjects affected / exposed	1 / 31 (3.23%)	1 / 35 (2.86%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cystitis	Additional description: Cystitis		
subjects affected / exposed	1 / 31 (3.23%)	0 / 35 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cytomegalovirus oesophagitis	Additional description: Cytomegalovirus oesophagitis		
subjects affected / exposed	1 / 31 (3.23%)	0 / 35 (0.00%)	
occurrences causally related to treatment / all	2 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Erysipelas	Additional description: Erysipelas		

subjects affected / exposed	0 / 31 (0.00%)	1 / 35 (2.86%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Febrile infection	Additional description: Febrile infection		
subjects affected / exposed	0 / 31 (0.00%)	1 / 35 (2.86%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
H1n1 influenza	Additional description: H1n1 influenza		
subjects affected / exposed	1 / 31 (3.23%)	0 / 35 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatitis viral	Additional description: Hepatitis viral		
subjects affected / exposed	0 / 31 (0.00%)	1 / 35 (2.86%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Herpes zoster	Additional description: Herpes zoster		
subjects affected / exposed	0 / 31 (0.00%)	1 / 35 (2.86%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infection	Additional description: Infection		
subjects affected / exposed	2 / 31 (6.45%)	0 / 35 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Influenza	Additional description: Influenza		
subjects affected / exposed	0 / 31 (0.00%)	1 / 35 (2.86%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Legionella infection	Additional description: Legionella infection		
subjects affected / exposed	0 / 31 (0.00%)	1 / 35 (2.86%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neutropenic infection	Additional description: Neutropenic infection		

subjects affected / exposed	0 / 31 (0.00%)	1 / 35 (2.86%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia herpes viral	Additional description: Pneumonia herpes viral		
subjects affected / exposed	1 / 31 (3.23%)	0 / 35 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Parainfluenzae virus infection	Additional description: Parainfluenzae virus infection		
subjects affected / exposed	1 / 31 (3.23%)	0 / 35 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peritonsillar abscess	Additional description: Peritonsillar abscess		
subjects affected / exposed	1 / 31 (3.23%)	0 / 35 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia	Additional description: Pneumonia		
subjects affected / exposed	4 / 31 (12.90%)	0 / 35 (0.00%)	
occurrences causally related to treatment / all	7 / 10	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pseudomonas infection	Additional description: Pseudomonas infection		
subjects affected / exposed	1 / 31 (3.23%)	0 / 35 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pseudomonal sepsis	Additional description: Pseudomonal sepsis		
subjects affected / exposed	1 / 31 (3.23%)	0 / 35 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin infection	Additional description: Skin infection		
subjects affected / exposed	1 / 31 (3.23%)	0 / 35 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sinusitis	Additional description: Sinusitis		

subjects affected / exposed	1 / 31 (3.23%)	0 / 35 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sepsis	Additional description: Sepsis		
subjects affected / exposed	3 / 31 (9.68%)	0 / 35 (0.00%)	
occurrences causally related to treatment / all	3 / 3	0 / 0	
deaths causally related to treatment / all	3 / 3	0 / 0	
Scrotal abscess	Additional description: Scrotal abscess		
subjects affected / exposed	1 / 31 (3.23%)	0 / 35 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary sepsis	Additional description: Pulmonary sepsis		
subjects affected / exposed	1 / 31 (3.23%)	0 / 35 (0.00%)	
occurrences causally related to treatment / all	2 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory tract infection	Additional description: Respiratory tract infection		
subjects affected / exposed	0 / 31 (0.00%)	1 / 35 (2.86%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract infection	Additional description: Urinary tract infection		
subjects affected / exposed	2 / 31 (6.45%)	0 / 35 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Upper respiratory tract infection	Additional description: Upper respiratory tract infection		
subjects affected / exposed	0 / 31 (0.00%)	1 / 35 (2.86%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urosepsis	Additional description: Urosepsis		
subjects affected / exposed	1 / 31 (3.23%)	0 / 35 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
Hypercalcaemia	Additional description: Hypercalcaemia		



subjects affected / exposed	0 / 31 (0.00%)	1 / 35 (2.86%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tumour lysis syndrome	Additional description: Tumour lysis syndrome		
subjects affected / exposed	2 / 31 (6.45%)	1 / 35 (2.86%)	
occurrences causally related to treatment / all	2 / 2	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	RR patient	FL patient	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	29 / 31 (93.55%)	35 / 35 (100.00%)	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Acoustic neuroma	Additional description: Acoustic neuroma		
subjects affected / exposed	0 / 31 (0.00%)	1 / 35 (2.86%)	
occurrences (all)	0	1	
Keratoacanthoma	Additional description: Keratoacanthoma		
subjects affected / exposed	1 / 31 (3.23%)	0 / 35 (0.00%)	
occurrences (all)	1	0	
Vascular disorders			
Circulatory collapse	Additional description: Circulatory collapse		
subjects affected / exposed	1 / 31 (3.23%)	0 / 35 (0.00%)	
occurrences (all)	1	0	
Haematoma	Additional description: Haematoma		
subjects affected / exposed	1 / 31 (3.23%)	1 / 35 (2.86%)	
occurrences (all)	1	1	
Hypotension	Additional description: Hypotension		
subjects affected / exposed	2 / 31 (6.45%)	0 / 35 (0.00%)	
occurrences (all)	2	0	
Hypertension	Additional description: Hypertension		
subjects affected / exposed	6 / 31 (19.35%)	5 / 35 (14.29%)	
occurrences (all)	7	5	
Phlebitis	Additional description: Phlebitis		

subjects affected / exposed	0 / 31 (0.00%)	1 / 35 (2.86%)	
occurrences (all)	0	1	
General disorders and administration site conditions			
Chest pain	Additional description: Chest pain		
subjects affected / exposed	1 / 31 (3.23%)	0 / 35 (0.00%)	
occurrences (all)	1	0	
Chills	Additional description: Chills		
subjects affected / exposed	0 / 31 (0.00%)	1 / 35 (2.86%)	
occurrences (all)	0	1	
Drug intolerance	Additional description: Drug intolerance		
subjects affected / exposed	0 / 31 (0.00%)	1 / 35 (2.86%)	
occurrences (all)	0	1	
Fatigue	Additional description: Fatigue		
subjects affected / exposed	8 / 31 (25.81%)	11 / 35 (31.43%)	
occurrences (all)	13	17	
Feeling cold	Additional description: Feeling cold		
subjects affected / exposed	0 / 31 (0.00%)	1 / 35 (2.86%)	
occurrences (all)	0	1	
Gait disturbance	Additional description: Gait disturbance		
subjects affected / exposed	0 / 31 (0.00%)	1 / 35 (2.86%)	
occurrences (all)	0	1	
General physical health deterioration	Additional description: General physical health deterioration		
subjects affected / exposed	0 / 31 (0.00%)	1 / 35 (2.86%)	
occurrences (all)	0	1	
Infusion site reaction	Additional description: Infusion site reaction		
subjects affected / exposed	0 / 31 (0.00%)	1 / 35 (2.86%)	
occurrences (all)	0	1	
Influenza like illness	Additional description: Influenza like illness		
subjects affected / exposed	0 / 31 (0.00%)	2 / 35 (5.71%)	
occurrences (all)	0	2	
Oedema peripheral	Additional description: Oedema peripheral		
subjects affected / exposed	1 / 31 (3.23%)	1 / 35 (2.86%)	
occurrences (all)	1	1	
Oedema	Additional description: Oedema		

subjects affected / exposed	1 / 31 (3.23%)	2 / 35 (5.71%)	
occurrences (all)	1	2	
Mucosal inflammation	Additional description: Mucosal inflammation		
subjects affected / exposed	1 / 31 (3.23%)	1 / 35 (2.86%)	
occurrences (all)	1	1	
Sensation of foreign body	Additional description: Sensation of foreign body		
subjects affected / exposed	0 / 31 (0.00%)	1 / 35 (2.86%)	
occurrences (all)	0	1	
Pyrexia	Additional description: Pyrexia		
subjects affected / exposed	2 / 31 (6.45%)	4 / 35 (11.43%)	
occurrences (all)	2	4	
Immune system disorders			
Drug hypersensitivity	Additional description: Drug hypersensitivity		
subjects affected / exposed	1 / 31 (3.23%)	0 / 35 (0.00%)	
occurrences (all)	1	0	
Hypogammaglobulinaemia	Additional description: Hypogammaglobulinaemia		
subjects affected / exposed	2 / 31 (6.45%)	0 / 35 (0.00%)	
occurrences (all)	2	0	
Hypersensitivity	Additional description: Hypersensitivity		
subjects affected / exposed	1 / 31 (3.23%)	1 / 35 (2.86%)	
occurrences (all)	4	1	
Oral allergy syndrome	Additional description: Oral allergy syndrome		
subjects affected / exposed	1 / 31 (3.23%)	0 / 35 (0.00%)	
occurrences (all)	1	0	
Reproductive system and breast disorders			
Pelvic pain	Additional description: Pelvic pain		
subjects affected / exposed	0 / 31 (0.00%)	2 / 35 (5.71%)	
occurrences (all)	0	2	
Respiratory, thoracic and mediastinal disorders			
Asthma	Additional description: Asthma		
subjects affected / exposed	1 / 31 (3.23%)	0 / 35 (0.00%)	
occurrences (all)	1	0	
Cough	Additional description: Cough		
subjects affected / exposed	5 / 31 (16.13%)	3 / 35 (8.57%)	
occurrences (all)	5	4	
Dry throat	Additional description: Dry throat		

subjects affected / exposed	1 / 31 (3.23%)	0 / 35 (0.00%)	
occurrences (all)	1	0	
Dyspnoea	Additional description: Dyspnoea		
subjects affected / exposed	2 / 31 (6.45%)	3 / 35 (8.57%)	
occurrences (all)	2	3	
Dyspnoea exertional	Additional description: Dyspnoea exertional		
subjects affected / exposed	2 / 31 (6.45%)	1 / 35 (2.86%)	
occurrences (all)	2	1	
Epistaxis	Additional description: Epistaxis		
subjects affected / exposed	3 / 31 (9.68%)	1 / 35 (2.86%)	
occurrences (all)	3	1	
Hiccups	Additional description: Hiccups		
subjects affected / exposed	0 / 31 (0.00%)	1 / 35 (2.86%)	
occurrences (all)	0	1	
Rhinorrhoea	Additional description: Rhinorrhoea		
subjects affected / exposed	0 / 31 (0.00%)	1 / 35 (2.86%)	
occurrences (all)	0	1	
Psychiatric disorders			
Anxiety	Additional description: Anxiety		
subjects affected / exposed	1 / 31 (3.23%)	0 / 35 (0.00%)	
occurrences (all)	1	0	
Confusional state	Additional description: Confusional state		
subjects affected / exposed	1 / 31 (3.23%)	0 / 35 (0.00%)	
occurrences (all)	1	0	
Depression	Additional description: Depression		
subjects affected / exposed	0 / 31 (0.00%)	1 / 35 (2.86%)	
occurrences (all)	0	1	
Insomnia	Additional description: Insomnia		
subjects affected / exposed	0 / 31 (0.00%)	2 / 35 (5.71%)	
occurrences (all)	0	3	
Sleep disorder	Additional description: Sleep disorder		
subjects affected / exposed	1 / 31 (3.23%)	0 / 35 (0.00%)	
occurrences (all)	1	0	
Stress	Additional description: Stress		
subjects affected / exposed	0 / 31 (0.00%)	1 / 35 (2.86%)	
occurrences (all)	0	1	

Tension subjects affected / exposed occurrences (all)	Additional description: Tension		
	0 / 31 (0.00%)	1 / 35 (2.86%)	
	0	1	
Investigations			
Alanine aminotransferase increased subjects affected / exposed occurrences (all)	Additional description: Alanine aminotransferase increased		
	1 / 31 (3.23%)	0 / 35 (0.00%)	
	1	0	
Aspartate aminotransferase increased subjects affected / exposed occurrences (all)	Additional description: Aspartate aminotransferase increased		
	1 / 31 (3.23%)	0 / 35 (0.00%)	
	1	0	
Blood bilirubin increased subjects affected / exposed occurrences (all)	Additional description: Blood bilirubin increased		
	1 / 31 (3.23%)	0 / 35 (0.00%)	
	1	0	
Blood glucose increased subjects affected / exposed occurrences (all)	Additional description: Blood glucose increased		
	0 / 31 (0.00%)	1 / 35 (2.86%)	
	0	1	
Blood lactate dehydrogenase increased subjects affected / exposed occurrences (all)	Additional description: Blood lactate dehydrogenase increased		
	2 / 31 (6.45%)	1 / 35 (2.86%)	
	2	1	
C-reactive protein increased subjects affected / exposed occurrences (all)	Additional description: C-reactive protein increased		
	1 / 31 (3.23%)	0 / 35 (0.00%)	
	2	0	
Cd4 lymphocytes decreased subjects affected / exposed occurrences (all)	Additional description: Cd4 lymphocytes decreased		
	0 / 31 (0.00%)	1 / 35 (2.86%)	
	0	1	
Gamma-glutamyltransferase increased subjects affected / exposed occurrences (all)	Additional description: Gamma-glutamyltransferase increased		
	0 / 31 (0.00%)	1 / 35 (2.86%)	
	0	1	
Haemoglobin decreased subjects affected / exposed occurrences (all)	Additional description: Haemoglobin decreased		
	1 / 31 (3.23%)	0 / 35 (0.00%)	
	1	0	
Lipase increased subjects affected / exposed occurrences (all)	Additional description: Lipase increased		
	0 / 31 (0.00%)	1 / 35 (2.86%)	
	0	1	
Transaminases increased	Additional description: Transaminases increased		

subjects affected / exposed	1 / 31 (3.23%)	1 / 35 (2.86%)	
occurrences (all)	1	1	
Weight increased	Additional description: Weight increased		
subjects affected / exposed	1 / 31 (3.23%)	1 / 35 (2.86%)	
occurrences (all)	3	1	
Injury, poisoning and procedural complications			
Arthropod bite	Additional description: Arthropod bite		
subjects affected / exposed	2 / 31 (6.45%)	0 / 35 (0.00%)	
occurrences (all)	2	0	
Contusion	Additional description: Contusion		
subjects affected / exposed	2 / 31 (6.45%)	0 / 35 (0.00%)	
occurrences (all)	2	0	
Eye injury	Additional description: Eye injury		
subjects affected / exposed	1 / 31 (3.23%)	0 / 35 (0.00%)	
occurrences (all)	1	0	
Fall	Additional description: Fall		
subjects affected / exposed	1 / 31 (3.23%)	1 / 35 (2.86%)	
occurrences (all)	1	1	
Laceration	Additional description: Laceration		
subjects affected / exposed	1 / 31 (3.23%)	0 / 35 (0.00%)	
occurrences (all)	1	0	
Infusion related reaction	Additional description: Infusion related reaction		
subjects affected / exposed	9 / 31 (29.03%)	9 / 35 (25.71%)	
occurrences (all)	10	10	
Muscle strain	Additional description: Muscle strain		
subjects affected / exposed	1 / 31 (3.23%)	0 / 35 (0.00%)	
occurrences (all)	1	0	
Wrist fracture	Additional description: Wrist fracture		
subjects affected / exposed	0 / 31 (0.00%)	1 / 35 (2.86%)	
occurrences (all)	0	1	
Cardiac disorders			
Atrial fibrillation	Additional description: Atrial fibrillation		
subjects affected / exposed	0 / 31 (0.00%)	1 / 35 (2.86%)	
occurrences (all)	0	1	
Cardiac failure	Additional description: Cardiac failure		

subjects affected / exposed	0 / 31 (0.00%)	1 / 35 (2.86%)	
occurrences (all)	0	1	
Coronary artery disease	Additional description: Coronary artery disease		
subjects affected / exposed	1 / 31 (3.23%)	0 / 35 (0.00%)	
occurrences (all)	1	0	
Microvascular coronary artery disease	Additional description: Microvascular coronary artery disease		
subjects affected / exposed	0 / 31 (0.00%)	1 / 35 (2.86%)	
occurrences (all)	0	1	
Pericardial effusion	Additional description: Pericardial effusion		
subjects affected / exposed	0 / 31 (0.00%)	1 / 35 (2.86%)	
occurrences (all)	0	1	
Palpitations	Additional description: Palpitations		
subjects affected / exposed	1 / 31 (3.23%)	1 / 35 (2.86%)	
occurrences (all)	1	1	
Supraventricular tachycardia	Additional description: Supraventricular tachycardia		
subjects affected / exposed	1 / 31 (3.23%)	0 / 35 (0.00%)	
occurrences (all)	2	0	
Tachycardia	Additional description: Tachycardia		
subjects affected / exposed	1 / 31 (3.23%)	3 / 35 (8.57%)	
occurrences (all)	1	3	
Ventricular extrasystoles	Additional description: Ventricular extrasystoles		
subjects affected / exposed	0 / 31 (0.00%)	1 / 35 (2.86%)	
occurrences (all)	0	1	
Nervous system disorders			
Amnesia	Additional description: Amnesia		
subjects affected / exposed	0 / 31 (0.00%)	1 / 35 (2.86%)	
occurrences (all)	0	1	
Disturbance in attention	Additional description: Disturbance in attention		
subjects affected / exposed	0 / 31 (0.00%)	1 / 35 (2.86%)	
occurrences (all)	0	1	
Dizziness	Additional description: Dizziness		
subjects affected / exposed	1 / 31 (3.23%)	0 / 35 (0.00%)	
occurrences (all)	1	0	
Dysaesthesia	Additional description: Dysaesthesia		

subjects affected / exposed	1 / 31 (3.23%)	0 / 35 (0.00%)	
occurrences (all)	1	0	
Headache	Additional description: Headache		
subjects affected / exposed	2 / 31 (6.45%)	4 / 35 (11.43%)	
occurrences (all)	2	7	
Hemianopia	Additional description: Hemianopia		
subjects affected / exposed	1 / 31 (3.23%)	0 / 35 (0.00%)	
occurrences (all)	1	0	
Parkinson's disease	Additional description: Parkinson's disease		
subjects affected / exposed	0 / 31 (0.00%)	1 / 35 (2.86%)	
occurrences (all)	0	1	
Sciatica	Additional description: Sciatica		
subjects affected / exposed	0 / 31 (0.00%)	1 / 35 (2.86%)	
occurrences (all)	0	1	
Post herpetic neuralgia	Additional description: Post herpetic neuralgia		
subjects affected / exposed	0 / 31 (0.00%)	1 / 35 (2.86%)	
occurrences (all)	0	1	
Radiculopathy	Additional description: Radiculopathy		
subjects affected / exposed	0 / 31 (0.00%)	1 / 35 (2.86%)	
occurrences (all)	0	1	
Blood and lymphatic system disorders			
Anaemia	Additional description: Anaemia		
subjects affected / exposed	6 / 31 (19.35%)	3 / 35 (8.57%)	
occurrences (all)	7	3	
Agranulocytosis	Additional description: Agranulocytosis		
subjects affected / exposed	0 / 31 (0.00%)	1 / 35 (2.86%)	
occurrences (all)	0	1	
Eosinophilia	Additional description: Eosinophilia		
subjects affected / exposed	0 / 31 (0.00%)	1 / 35 (2.86%)	
occurrences (all)	0	1	
Granulocytopenia	Additional description: Granulocytopenia		
subjects affected / exposed	1 / 31 (3.23%)	1 / 35 (2.86%)	
occurrences (all)	1	1	
Lymphadenopathy	Additional description: Lymphadenopathy		
subjects affected / exposed	1 / 31 (3.23%)	0 / 35 (0.00%)	
occurrences (all)	1	0	



Lymph node pain subjects affected / exposed occurrences (all)	Additional description: Lymph node pain		
	0 / 31 (0.00%)	2 / 35 (5.71%)	
	0	2	
Leukopenia subjects affected / exposed occurrences (all)	Additional description: Leukopenia		
	2 / 31 (6.45%)	2 / 35 (5.71%)	
	2	2	
Neutropenia subjects affected / exposed occurrences (all)	Additional description: Neutropenia		
	19 / 31 (61.29%)	15 / 35 (42.86%)	
	40	40	
Thrombocytopenia subjects affected / exposed occurrences (all)	Additional description: Thrombocytopenia		
	9 / 31 (29.03%)	4 / 35 (11.43%)	
	17	4	
Ear and labyrinth disorders Tinnitus subjects affected / exposed occurrences (all)	Additional description: Tinnitus		
	1 / 31 (3.23%)	0 / 35 (0.00%)	
	1	0	
Vertigo subjects affected / exposed occurrences (all)	Additional description: Vertigo		
	2 / 31 (6.45%)	4 / 35 (11.43%)	
	2	5	
Eye disorders Cataract subjects affected / exposed occurrences (all)	Additional description: Cataract		
	1 / 31 (3.23%)	0 / 35 (0.00%)	
	1	0	
	Additional description: Dry eye		
	1 / 31 (3.23%)	0 / 35 (0.00%)	
	1	0	
	Additional description: Eye irritation		
	0 / 31 (0.00%)	1 / 35 (2.86%)	
	0	1	
	Additional description: Eyelid oedema		
	1 / 31 (3.23%)	1 / 35 (2.86%)	
	1	1	
	Additional description: Vision blurred		
	1 / 31 (3.23%)	0 / 35 (0.00%)	
	1	0	
Gastrointestinal disorders			

Abdominal discomfort subjects affected / exposed occurrences (all)	Additional description: Abdominal discomfort 1 / 31 (3.23%) 1	0 / 35 (0.00%) 0	
Abdominal distension subjects affected / exposed occurrences (all)	Additional description: Abdominal distension 1 / 31 (3.23%) 2	2 / 35 (5.71%) 2	
Abdominal pain subjects affected / exposed occurrences (all)	Additional description: Abdominal pain 1 / 31 (3.23%) 1	2 / 35 (5.71%) 2	
Abdominal pain upper subjects affected / exposed occurrences (all)	Additional description: Abdominal pain upper 2 / 31 (6.45%) 2	2 / 35 (5.71%) 2	
Colitis subjects affected / exposed occurrences (all)	Additional description: Colitis 0 / 31 (0.00%) 0	1 / 35 (2.86%) 1	
Constipation subjects affected / exposed occurrences (all)	Additional description: Constipation 0 / 31 (0.00%) 0	4 / 35 (11.43%) 4	
Diarrhoea subjects affected / exposed occurrences (all)	Additional description: Diarrhoea 7 / 31 (22.58%) 9	7 / 35 (20.00%) 10	
Dyspepsia subjects affected / exposed occurrences (all)	Additional description: Dyspepsia 1 / 31 (3.23%) 1	1 / 35 (2.86%) 1	
Epigastric discomfort subjects affected / exposed occurrences (all)	Additional description: Epigastric discomfort 2 / 31 (6.45%) 3	1 / 35 (2.86%) 1	
Faeces soft subjects affected / exposed occurrences (all)	Additional description: Faeces soft 1 / 31 (3.23%) 1	0 / 35 (0.00%) 0	
Flatulence subjects affected / exposed occurrences (all)	Additional description: Flatulence 0 / 31 (0.00%) 0	3 / 35 (8.57%) 3	
Gastritis subjects affected / exposed occurrences (all)	Additional description: Gastritis 1 / 31 (3.23%) 1	0 / 35 (0.00%) 0	

Gastrointestinal pain subjects affected / exposed occurrences (all)	Additional description: Gastrointestinal pain	
	0 / 31 (0.00%) 0	1 / 35 (2.86%) 1
Loose tooth subjects affected / exposed occurrences (all)	Additional description: Loose tooth	
	0 / 31 (0.00%) 0	1 / 35 (2.86%) 1
Nausea subjects affected / exposed occurrences (all)	Additional description: Nausea	
	6 / 31 (19.35%) 8	10 / 35 (28.57%) 11
Stomatitis subjects affected / exposed occurrences (all)	Additional description: Stomatitis	
	1 / 31 (3.23%) 1	0 / 35 (0.00%) 0
Toothache subjects affected / exposed occurrences (all)	Additional description: Toothache	
	1 / 31 (3.23%) 1	0 / 35 (0.00%) 0
Vomiting subjects affected / exposed occurrences (all)	Additional description: Vomiting	
	2 / 31 (6.45%) 2	3 / 35 (8.57%) 4
Hepatobiliary disorders Cholangitis subjects affected / exposed occurrences (all)	Additional description: Cholangitis	
	1 / 31 (3.23%) 1	0 / 35 (0.00%) 0
Skin and subcutaneous tissue disorders Dermal cyst subjects affected / exposed occurrences (all)	Additional description: Dermal cyst	
	0 / 31 (0.00%) 0	1 / 35 (2.86%) 1
Dry skin subjects affected / exposed occurrences (all)	Additional description: Dry skin	
	0 / 31 (0.00%) 0	1 / 35 (2.86%) 1
Erythema subjects affected / exposed occurrences (all)	Additional description: Erythema	
	0 / 31 (0.00%) 0	1 / 35 (2.86%) 1
Drug eruption subjects affected / exposed occurrences (all)	Additional description: Drug eruption	
	0 / 31 (0.00%) 0	1 / 35 (2.86%) 1
Hyperhidrosis	Additional description: Hyperhidrosis	

subjects affected / exposed	0 / 31 (0.00%)	1 / 35 (2.86%)	
occurrences (all)	0	1	
Night sweats	Additional description: Night sweats		
subjects affected / exposed	0 / 31 (0.00%)	1 / 35 (2.86%)	
occurrences (all)	0	1	
Petechiae	Additional description: Petechiae		
subjects affected / exposed	1 / 31 (3.23%)	1 / 35 (2.86%)	
occurrences (all)	1	1	
Rash	Additional description: Rash		
subjects affected / exposed	4 / 31 (12.90%)	8 / 35 (22.86%)	
occurrences (all)	4	9	
Rash papular	Additional description: Rash papular		
subjects affected / exposed	1 / 31 (3.23%)	0 / 35 (0.00%)	
occurrences (all)	1	0	
Skin reaction	Additional description: Skin reaction		
subjects affected / exposed	0 / 31 (0.00%)	1 / 35 (2.86%)	
occurrences (all)	0	1	
Pruritus	Additional description: Pruritus		
subjects affected / exposed	0 / 31 (0.00%)	2 / 35 (5.71%)	
occurrences (all)	0	3	
Psoriasis	Additional description: Psoriasis		
subjects affected / exposed	0 / 31 (0.00%)	1 / 35 (2.86%)	
occurrences (all)	0	1	
Renal and urinary disorders			
Dysuria	Additional description: Dysuria		
subjects affected / exposed	0 / 31 (0.00%)	1 / 35 (2.86%)	
occurrences (all)	0	1	
Haematuria	Additional description: Haematuria		
subjects affected / exposed	1 / 31 (3.23%)	0 / 35 (0.00%)	
occurrences (all)	1	0	
Polyuria	Additional description: Polyuria		
subjects affected / exposed	0 / 31 (0.00%)	1 / 35 (2.86%)	
occurrences (all)	0	1	
Endocrine disorders			
Androgen deficiency	Additional description: Androgen deficiency		

subjects affected / exposed	1 / 31 (3.23%)	0 / 35 (0.00%)	
occurrences (all)	1	0	
Hyperparathyroidism	Additional description: Hyperparathyroidism		
subjects affected / exposed	1 / 31 (3.23%)	0 / 35 (0.00%)	
occurrences (all)	1	0	
Musculoskeletal and connective tissue disorders			
Arthralgia	Additional description: Arthralgia		
subjects affected / exposed	5 / 31 (16.13%)	1 / 35 (2.86%)	
occurrences (all)	6	1	
Arthritis	Additional description: Arthritis		
subjects affected / exposed	0 / 31 (0.00%)	1 / 35 (2.86%)	
occurrences (all)	0	1	
Back pain	Additional description: Back pain		
subjects affected / exposed	5 / 31 (16.13%)	2 / 35 (5.71%)	
occurrences (all)	6	2	
Bone pain	Additional description: Bone pain		
subjects affected / exposed	1 / 31 (3.23%)	0 / 35 (0.00%)	
occurrences (all)	1	0	
Diastasis recti abdominis	Additional description: Diastasis recti abdominis		
subjects affected / exposed	0 / 31 (0.00%)	1 / 35 (2.86%)	
occurrences (all)	0	1	
Flank pain	Additional description: Flank pain		
subjects affected / exposed	0 / 31 (0.00%)	1 / 35 (2.86%)	
occurrences (all)	0	1	
Groin pain	Additional description: Groin pain		
subjects affected / exposed	1 / 31 (3.23%)	0 / 35 (0.00%)	
occurrences (all)	1	0	
Pain in extremity	Additional description: Pain in extremity		
subjects affected / exposed	1 / 31 (3.23%)	2 / 35 (5.71%)	
occurrences (all)	1	2	
Nuchal rigidity	Additional description: Nuchal rigidity		
subjects affected / exposed	1 / 31 (3.23%)	0 / 35 (0.00%)	
occurrences (all)	1	0	
Myalgia	Additional description: Myalgia		

subjects affected / exposed	3 / 31 (9.68%)	1 / 35 (2.86%)	
occurrences (all)	3	2	
Musculoskeletal stiffness	Additional description: Musculoskeletal stiffness		
subjects affected / exposed	1 / 31 (3.23%)	1 / 35 (2.86%)	
occurrences (all)	1	1	
Infections and infestations			
Acute sinusitis	Additional description: Acute sinusitis		
subjects affected / exposed	1 / 31 (3.23%)	0 / 35 (0.00%)	
occurrences (all)	1	0	
Bacterial prostatitis	Additional description: Bacterial prostatitis		
subjects affected / exposed	0 / 31 (0.00%)	1 / 35 (2.86%)	
occurrences (all)	0	1	
Borrelia infection	Additional description: Borrelia infection		
subjects affected / exposed	0 / 31 (0.00%)	1 / 35 (2.86%)	
occurrences (all)	0	1	
Bronchitis	Additional description: Bronchitis		
subjects affected / exposed	5 / 31 (16.13%)	11 / 35 (31.43%)	
occurrences (all)	9	11	
Campylobacter gastroenteritis	Additional description: Campylobacter gastroenteritis		
subjects affected / exposed	0 / 31 (0.00%)	1 / 35 (2.86%)	
occurrences (all)	0	1	
Chronic sinusitis	Additional description: Chronic sinusitis		
subjects affected / exposed	1 / 31 (3.23%)	0 / 35 (0.00%)	
occurrences (all)	1	0	
Diverticulitis	Additional description: Diverticulitis		
subjects affected / exposed	1 / 31 (3.23%)	0 / 35 (0.00%)	
occurrences (all)	1	0	
Clostridial infection	Additional description: Clostridial infection		
subjects affected / exposed	0 / 31 (0.00%)	1 / 35 (2.86%)	
occurrences (all)	0	1	
Conjunctivitis	Additional description: Conjunctivitis		
subjects affected / exposed	2 / 31 (6.45%)	0 / 35 (0.00%)	
occurrences (all)	2	0	
Covid-19	Additional description: Covid-19		
subjects affected / exposed	0 / 31 (0.00%)	4 / 35 (11.43%)	
occurrences (all)	0	7	

Cystitis	Additional description: Cystitis	
subjects affected / exposed	4 / 31 (12.90%)	1 / 35 (2.86%)
occurrences (all)	13	1
Cytomegalovirus infection reactivation	Additional description: Cytomegalovirus infection reactivation	
subjects affected / exposed	1 / 31 (3.23%)	0 / 35 (0.00%)
occurrences (all)	1	0
Ear infection	Additional description: Ear infection	
subjects affected / exposed	0 / 31 (0.00%)	1 / 35 (2.86%)
occurrences (all)	0	1
Epididymitis	Additional description: Epididymitis	
subjects affected / exposed	1 / 31 (3.23%)	0 / 35 (0.00%)
occurrences (all)	1	0
Fungal skin infection	Additional description: Fungal skin infection	
subjects affected / exposed	0 / 31 (0.00%)	1 / 35 (2.86%)
occurrences (all)	0	1
Gastroenteritis	Additional description: Gastroenteritis	
subjects affected / exposed	0 / 31 (0.00%)	1 / 35 (2.86%)
occurrences (all)	0	1
Gastroenteritis clostridial	Additional description: Gastroenteritis clostridial	
subjects affected / exposed	0 / 31 (0.00%)	1 / 35 (2.86%)
occurrences (all)	0	1
Genital herpes	Additional description: Genital herpes	
subjects affected / exposed	1 / 31 (3.23%)	0 / 35 (0.00%)
occurrences (all)	1	0
Gingivitis	Additional description: Gingivitis	
subjects affected / exposed	1 / 31 (3.23%)	1 / 35 (2.86%)
occurrences (all)	1	1
Haemophilus infection	Additional description: Haemophilus infection	
subjects affected / exposed	1 / 31 (3.23%)	0 / 35 (0.00%)
occurrences (all)	1	0
Helicobacter gastritis	Additional description: Helicobacter gastritis	
subjects affected / exposed	1 / 31 (3.23%)	0 / 35 (0.00%)
occurrences (all)	1	0
Herpes simplex	Additional description: Herpes simplex	

subjects affected / exposed	0 / 31 (0.00%)	1 / 35 (2.86%)	
occurrences (all)	0	3	
Herpes virus infection	Additional description: Herpes virus infection		
subjects affected / exposed	1 / 31 (3.23%)	0 / 35 (0.00%)	
occurrences (all)	1	0	
Herpes zoster	Additional description: Herpes zoster		
subjects affected / exposed	2 / 31 (6.45%)	3 / 35 (8.57%)	
occurrences (all)	2	3	
Influenza	Additional description: Influenza		
subjects affected / exposed	3 / 31 (9.68%)	0 / 35 (0.00%)	
occurrences (all)	3	0	
Infection	Additional description: Infection		
subjects affected / exposed	1 / 31 (3.23%)	5 / 35 (14.29%)	
occurrences (all)	2	6	
Infected bites	Additional description: Infected bites		
subjects affected / exposed	0 / 31 (0.00%)	1 / 35 (2.86%)	
occurrences (all)	0	1	
Parotitis	Additional description: Parotitis		
subjects affected / exposed	0 / 31 (0.00%)	1 / 35 (2.86%)	
occurrences (all)	0	1	
Paronychia	Additional description: Paronychia		
subjects affected / exposed	0 / 31 (0.00%)	1 / 35 (2.86%)	
occurrences (all)	0	1	
Papilloma viral infection	Additional description: Papilloma viral infection		
subjects affected / exposed	1 / 31 (3.23%)	0 / 35 (0.00%)	
occurrences (all)	1	0	
Oral herpes	Additional description: Oral herpes		
subjects affected / exposed	2 / 31 (6.45%)	1 / 35 (2.86%)	
occurrences (all)	2	1	
Oral candidiasis	Additional description: Oral candidiasis		
subjects affected / exposed	2 / 31 (6.45%)	0 / 35 (0.00%)	
occurrences (all)	2	0	
Onychomycosis	Additional description: Onychomycosis		
subjects affected / exposed	0 / 31 (0.00%)	1 / 35 (2.86%)	
occurrences (all)	0	1	
Nasopharyngitis	Additional description: Nasopharyngitis		



subjects affected / exposed	11 / 31 (35.48%)	9 / 35 (25.71%)	
occurrences (all)	15	11	
Periodontitis	Additional description: Periodontitis		
subjects affected / exposed	1 / 31 (3.23%)	0 / 35 (0.00%)	
occurrences (all)	1	0	
Respiratory tract infection	Additional description: Respiratory tract infection		
subjects affected / exposed	1 / 31 (3.23%)	2 / 35 (5.71%)	
occurrences (all)	2	2	
Rhinitis	Additional description: Rhinitis		
subjects affected / exposed	0 / 31 (0.00%)	3 / 35 (8.57%)	
occurrences (all)	0	3	
Sinusitis	Additional description: Sinusitis		
subjects affected / exposed	2 / 31 (6.45%)	5 / 35 (14.29%)	
occurrences (all)	3	11	
Skin infection	Additional description: Skin infection		
subjects affected / exposed	1 / 31 (3.23%)	2 / 35 (5.71%)	
occurrences (all)	1	2	
Subcutaneous abscess	Additional description: Subcutaneous abscess		
subjects affected / exposed	1 / 31 (3.23%)	0 / 35 (0.00%)	
occurrences (all)	1	0	
Pneumonia	Additional description: Pneumonia		
subjects affected / exposed	4 / 31 (12.90%)	3 / 35 (8.57%)	
occurrences (all)	6	3	
Pneumonia fungal	Additional description: Pneumonia fungal		
subjects affected / exposed	1 / 31 (3.23%)	0 / 35 (0.00%)	
occurrences (all)	1	0	
Pulpitis dental	Additional description: Pulpitis dental		
subjects affected / exposed	0 / 31 (0.00%)	1 / 35 (2.86%)	
occurrences (all)	0	1	
Upper respiratory tract infection	Additional description: Upper respiratory tract infection		
subjects affected / exposed	8 / 31 (25.81%)	11 / 35 (31.43%)	
occurrences (all)	14	15	
Urethritis	Additional description: Urethritis		
subjects affected / exposed	0 / 31 (0.00%)	2 / 35 (5.71%)	
occurrences (all)	0	2	
Urinary tract infection	Additional description: Urinary tract infection		

subjects affected / exposed occurrences (all)	3 / 31 (9.68%) 3	3 / 35 (8.57%) 3	
Varicella zoster virus infection	Additional description: Varicella zoster virus infection		
subjects affected / exposed occurrences (all)	0 / 31 (0.00%) 0	1 / 35 (2.86%) 1	
Viral infection	Additional description: Viral infection		
subjects affected / exposed occurrences (all)	0 / 31 (0.00%) 0	1 / 35 (2.86%) 2	
Vulvovaginal candidiasis	Additional description: Vulvovaginal candidiasis		
subjects affected / exposed occurrences (all)	0 / 31 (0.00%) 0	1 / 35 (2.86%) 1	
Vulvovaginal mycotic infection	Additional description: Vulvovaginal mycotic infection		
subjects affected / exposed occurrences (all)	0 / 31 (0.00%) 0	1 / 35 (2.86%) 1	
Tonsillitis	Additional description: Tonsillitis		
subjects affected / exposed occurrences (all)	0 / 31 (0.00%) 0	1 / 35 (2.86%) 1	
Metabolism and nutrition disorders			
Abnormal loss of weight	Additional description: Abnormal loss of weight		
subjects affected / exposed occurrences (all)	1 / 31 (3.23%) 1	0 / 35 (0.00%) 0	
Gout	Additional description: Gout		
subjects affected / exposed occurrences (all)	0 / 31 (0.00%) 0	1 / 35 (2.86%) 1	
Increased appetite	Additional description: Increased appetite		
subjects affected / exposed occurrences (all)	0 / 31 (0.00%) 0	1 / 35 (2.86%) 1	
Hypophosphataemia	Additional description: Hypophosphataemia		
subjects affected / exposed occurrences (all)	0 / 31 (0.00%) 0	1 / 35 (2.86%) 1	
Hypokalaemia	Additional description: Hypokalaemia		
subjects affected / exposed occurrences (all)	2 / 31 (6.45%) 4	1 / 35 (2.86%) 1	
Hyperuricaemia	Additional description: Hyperuricaemia		
subjects affected / exposed occurrences (all)	2 / 31 (6.45%) 2	0 / 35 (0.00%) 0	

Hyperkalaemia subjects affected / exposed occurrences (all)	Additional description: Hyperkalaemia	
	2 / 31 (6.45%) 2	1 / 35 (2.86%) 1
Tumour lysis syndrome subjects affected / exposed occurrences (all)	Additional description: Tumour lysis syndrome	
	1 / 31 (3.23%) 1	0 / 35 (0.00%) 0
Vitamin d deficiency subjects affected / exposed occurrences (all)	Additional description: Vitamin d deficiency	
	0 / 31 (0.00%) 0	1 / 35 (2.86%) 1

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
21 October 2015	Amendment following updated Obinutsumab IB
07 June 2017	New IB for Venetoclax and Obinutsumab, adjustments and specifications of the statistical chapter were made
22 August 2018	New IB for Venetoclax and Obinutsumab
11 November 2019	The possibility of a retreatment was added, prolongation of the follow-up period
03 May 2021	Extension of Re-Screening period until Q1/2022
27 June 2022	new SmPCs for alle study drugs
29 March 2023	updated SmPCs for Venetoclax, Obinutuzumab and Bendamustin - non-substantial
03 July 2024	updated SmPCs for Venetoclax, Obinutuzumab and Bendamustin - non-substantial
29 October 2024	updated SmPCs for Venetoclax, Obinutuzumab and Bendamustin - non-substantial

Notes:

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

none reported

Notes:

### Online references

<http://www.ncbi.nlm.nih.gov/pubmed/30115596>